Epidermal growth factor receptors and prognosis in primary breast cancer

Spyratos, Frédérique; Delarue, J; Andrieu, Catherine; Lidereau, Rosette; Champème, Marie-Hélène; Hacène, K.; Brunet, M

doi:10.1007/bf01806288

Cited by 53 publications

(29 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, in the present study we did not observe a correlation of EGFR with steroid hormone receptor and this is in agreement with some other studies (Fitzpatrick et al, 1984;Peyrat et al, 1984;Bevilacqua et al, 1990) but in disagreement with the majority of authors who reported a significant inverse relationship between EGFR expression and ER-positivity (Koenders et al, 1991;Sainsbury et al, 1987;Lewis et al, 1990;Spyratos et al, 1990). There is also conflicting data in the literature regarding the relationship between EGFR and cell kinetics parameters in human breast carcinoma (Walker & Camplejohn, 1986;Gasparini et al, 1991).…”

Section: Monthssupporting

confidence: 92%

“…Thus, in our experience, the overall picture is that EGFR status seems to be independent not only from the conventional pathologic parameters but also from some of the new (Foekens et al, 1989;Spyratos et al, 1990). In our series EGFR status is a significant prognostic factor for recurrence, but not for overall survival when evaluated by univariate analysis.…”

Section: Monthssupporting

confidence: 52%

See 1 more Smart Citation

Value of epidermal growth factor receptor status compared with growth fraction and other factors for prognosis in early breast cancer

Gasparini

Bevilacqua²,

Pozza³

et al. 1992

Br J Cancer

View full text Add to dashboard Cite

Summary The epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein whose expression is important in the regulation of breast cancer cell growth. The relationship between EGFR status (determined by an immunocytochemical assay) and various prognostic factors was investigated in 164 primary breast cancers. Overall 56% of tumours were EGFR-positive and the expression of EGFR was unrelated to axillary node status, tumour size and histological grade; and it was poorly associated with the tumour proliferative activity measured by Ki-67 immuno-cytochemistry. The relapse-free survival (RFS) probability at 3-years was significantly worse for patients with EGFR positive tumours (P = 0.003) and for those whose Ki-67 score was >7.5% (P = 0.0027), as well as in patients with axillary node involvement (P = 0.01) and with poorly differentiated tumours (P = 0.04). Immunocytochemical determination of EGFR and cell kinetics gave superimposable prognostic information for predicting RFS with odds ratios of 3.51, when evaluated singly. In our series of patients EGFR, Ki-67 and node status retain their prognostic value concerning RFS in multivariate analysis. The 3-year probability of overall survival (OS) was significantly better in node-negative patients (P = 0.04) and was similar in EGFR-positive and negative patients.In conclusion, EGFR status appears to be a significant and independent indicator of recurrence in human breast cancer and the concomitant measurement of the tumour proliferative activity seems to improve the selection of patients with different risks of recurrence.

show abstract

Section: Monthssupporting

confidence: 92%

Section: Monthssupporting

confidence: 52%

Value of epidermal growth factor receptor status compared with growth fraction and other factors for prognosis in early breast cancer

Gasparini

Bevilacqua²,

Pozza³

et al. 1992

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…We also report that SHBG inhibits the estradiol induction of EGF-R. EGF-R or HER1 is a member of the epidermal growth factor family of trans-membrane receptors [29] and it has been reported to be induced by estradiol [30] . Overexpression of EGF-R in breast cancer, that has been reported to occur in up to 14 % of tumors [31] , is considered a negative prognostic factor [32] , especially if it occurs together with over-expression of other genes such as c-myc [33] . Moreover, EGF-R is involved in a bidirectional cross-talk with estrogen receptors and the activation of the EGF-R-derived signaling pathway could amplify estradiol effect in breast cancer [34] .…”

Section: Discussionmentioning

confidence: 99%

Sex Hormone-binding Globulin Selectively Modulates Estradiol-regulated Genes in MCF-7 Cells

Catalano¹,

Costantino²,

Frairia³

et al. 2007

Horm Metab Res

View full text Add to dashboard Cite

&Human sex hormone-binding globulin inhibits the effects of estradiol on proliferation and apoptosis of breast cancer cells. We report here the effect of sex hormone-binding globulin on estradiol regulation of gene expression in MCF-7 breast cancer cells using a selected set of genes. Estradiol upregulates genes that are positive regulators of proliferation (e.g., bcl-2, c-fos, cmyc, cyclin D) or / and related to more aggressive form of breast cancer (e.g. BRCA-1, EGF-R) and downregulates two genes (c-jun and ER ).Sex hormone-binding globulin modulates only a selected group of estradiol-controlled genes (inhibiting upregulation of bcl-2, c-myc, EGF-R, PR, and downregulation of ER ), starting 48 hours after treatment. Our study demonstrates that in breast cancer cells, sex hormone-binding globulin is effective on few selected genes which are involved in cell growth and apoptosis or related to cell estrogen-dependence and that the protein regulation of estradiol effect is selected and specifi c. Sex hormone-binding globulin action in estrogen breast cancer cells is strongly associated to cell growth and estrogen-sensitivity.

show abstract

“…EGFR is located on 7q12 and codes for the EGFR, a transmembranous receptor protein with kinase activity. EGFR was found amplified in 0 to 14% of breast cancers (13,32). The role of EGFR has regained interest in breast cancer because EGFR interacts with HER2, a therapeutic target protein and because of the availability of drugs that directly target EGFR.…”

Section: Introductionmentioning

confidence: 99%

Prognostic Relevance of Gene Amplifications and Coamplifications in Breast Cancer

et al. 2004

View full text Add to dashboard Cite

Multiple different oncogenes have been described previously to be amplified in breast cancer including HER2, EGFR, MYC, CCND1, and MDM2. Gene amplification results in oncogene overexpression but may also serve as an indicator of genomic instability. As such, presence of one or several gene amplifications may have prognostic significance. To assess the prognostic importance of amplifications and coamplifications of HER2, EGFR, MYC, CCND1, and MDM2 in breast cancer, we analyzed a breast cancer tissue microarray containing samples from 2197 cancers with follow-up information. Fluorescence in situ hybridizations revealed amplifications of CCND1 in 20.1%, HER2 in 17.3%, MDM2 in 5.7%, MYC in 5.3%, and EGFR in 0.8% of the tumors. All gene amplifications were significantly associated with high grade. HER2 (P < 0.001) and MYC amplification (P < 0.001) were also linked to shortened survival. In case of HER2, this was independent of grade, pT, and pN categories. MYC amplification was almost 3 times more frequent in medullary cancer (15.9%), than in the histologic subtype with the second highest frequency (ductal; 5.6%; P ‫؍‬ 0.0046). HER2 and MYC amplification were associated with estrogen receptor/progesterone receptor negativity (P < 0.001) whereas CCND1 amplification was linked to estrogen receptor/progesterone receptor positivity (P < 0.001). Coamplifications were more prevalent than expected based on the individual frequencies. Coamplifications of one or several other oncogenes occurred in 29.6% of CCND1, 43% of HER2, 55.7% of MDM2, 65% of MYC, and 72.8% of EGFR-amplified cancers. HER2/MYC-coamplified cancers had a worse prognosis than tumors with only one of these amplifications. Furthermore, a gradual decrease of survival was observed with increasing number of amplifications. In conclusion, these data support a major prognostic impact of genomic instability as determined by a broad gene amplification survey in breast cancer.

show abstract

Epidermal growth factor receptors and prognosis in primary breast cancer

Cited by 53 publications

References 30 publications

Value of epidermal growth factor receptor status compared with growth fraction and other factors for prognosis in early breast cancer

Value of epidermal growth factor receptor status compared with growth fraction and other factors for prognosis in early breast cancer

Sex Hormone-binding Globulin Selectively Modulates Estradiol-regulated Genes in MCF-7 Cells

Prognostic Relevance of Gene Amplifications and Coamplifications in Breast Cancer

Contact Info

Product

Resources

About